GLP-1s are shrinking bodies. Enter cadaver fat injections
7 hours ago
- #medical-innovation
- #cadaver-ethics
- #plastic-surgery
- Sandra, a 43-year-old lawyer, tried alloClae, an injectable breast enhancement using cadaver fat, due to its minimal downtime and no surgery.
- AlloClae is marketed as 'off-the-shelf' fat grafting, gaining popularity with over 2,000 patients since May 2025, despite being called 'zombie filler'.
- The product is rising in demand partly due to weight-loss drugs like Ozempic, which cause volume loss, leading patients to seek re-volumizing in areas like breasts and buttocks.
- Ethical concerns exist around cadaver fat donation, as families may not fully consent, and regulation is lax, with New York blocking alloClae over compliance issues.
- Complications like fat necrosis occurred in some patients, such as Sandra, who experienced pain, discoloration, and fluid leakage, though the company denies confirmed rejection cases.
- AlloClae is compared to Botox in its potential to become mainstream, with proponents arguing it boosts confidence, while critics see it as a disturbing convenience.